Navigation Links
Cancer gene mystery to be cracked!

A major research project is to be launched by researchers from the UK and Netherlands in the hope of identifying the cluster of genes associated with cancer. The research will be led by Dr. Julian Downward from Cancer Research UK’s London Research Institute, along with Dr. René Bernards of the Netherlands Cancer Institute. This research will build on the success of the human genome project and will have scientists looking at nearly 10,000 genes, inactivating one at a time to find out precisely what they do and how they contribute to the development of cancer. They hope// that this effort will ultimately lead to the creation of new drugs that target rogue cancer-causing genes.

Scientists will use a process called RNA interference to switch off certain genes and leave others unaffected. This process was first identified as taking place in the nematode worm. It was discovered that the worm used tiny pieces of double-stranded RNA to switch off rogue genes that would otherwise harm it. Subsequently, researchers found that synthetically produced RNA sequences could be used to target genes in human cells. Using this discovery, scientists will bombard cancer cells with 30,000 pieces of interference RNA in an effort to discover the genetic essence of a malignant cell. The researchers will then screen the treated cells for those that have reverted to type and become normal again. They hope that those genes switched off by RNA interference in these cells may represent a crucial group of genes, which future anti-cancer drugs could target.

Dr. Downward concluded that they were confident that they would precisely find out what needs to be taken away from cancerous cells to make it normal again. Sir Paul Nurse, Chief Executive of Cancer Research, UK, on the other hand, added that the next challenge for scientists was to unravel the mystery of each human gene and find out what each gene was doing. This would help in working out which of them are playing import ant roles in cancer and other diseases.

'"/>




Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2016)... ... May 06, 2016 , ... The National Association of Chain ... in Puerto Rico. Radio messages set to debut on Monday, May 9, and ... about ways to protect themselves and their unborn children from the effects of ...
(Date:5/6/2016)... ... May 06, 2016 , ... DrugDev President and CEO Ibraheem ... pharmaceutical industry conducts clinical trials. This month Ibs was named No. 20 on The ... he was honored as a Tech Disruptor by the Philadelphia Business Journal. , Stephanie ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... ... Bluvault's Integration Service, their latest implementation service offering for global clients of Coupa ... Appterra ). , Bluvault’s Integration Service is a key component in the ...
(Date:5/6/2016)... ... 06, 2016 , ... From May 4 to 6, EarQ and ... opportunity to learn more about Signia’s technology and the successful business and marketing techniques ... priority to see practices succeed in this highly competitive industry,” said Ed Keller, president ...
(Date:5/6/2016)... ... May 06, 2016 , ... Multiple award winning plumbing ... operated for over 35 years. Maintaining core values of exceptional customer service, quality work ... made them a leading name in San Diego plumbing, and other services including heating ...
Breaking Medicine News(10 mins):
(Date:5/6/2016)... , May 6, 2016  Hill-Rom Holdings, Inc. (NYSE: ... of Directors declared a fiscal year 2016 third quarter ... percent increase over the amount paid a year ago. ... record as of the close of business on June 10, ...    Hill-Rom is a leading global medical technology ...
(Date:5/5/2016)... Ltd. today reported initial promising results in animal trials of its Zika vaccine candidates. ... ... ... ... Pubmed. The analysis identified the highest gene Replikin Counts in Zika history back to ...
(Date:5/5/2016)... , First quarter 2016 adjusted diluted earnings per share ... , First quarter reported diluted (GAAP) loss per share ... revises 2016 financial guidance; now expects 2016 revenues to range ... non-GAAP earnings per share to range from $4.50 to $4.80 ... and manufacturing facility restructuring , Company expands ...
Breaking Medicine Technology: